In selected higher risk adjuvant situations, imatinib is recommended for 3 years.Imatinib was approved for metastatic and unresectable GIST by the US FDA, February 1, 2002. The two-year survival of patients with advanced disease has risen to 75–80% following imatinib treatment.If resistance to imatinib is encountered, the multiple tyrosine kinase inhibitor sunitinib (marketed as Sutent) can be considered. : 26 and 31 The effectiveness of imatinib and sunitinib depend on the genotype. c-KIT- and PDGFRA-mutation negative GIST tumors are usually resistant to treatment with imatinib, as is neurofibromatosis-1-associated wild-type GIST. A specific subtype of PDGFRA mutation, D842V, is also insensitive to imatinib. Recently, in PDGFRA-mutated GIST, avapritinib has been approved by FDA. Now there are real-world data coming for avapritinib as well (Dr Sameer Rastogi, et al. )Regorafenib (Stivarga) was FDA-approved in 2013 for advanced GISTs that cannot be surgically removed and that no longer respond to imatinib (Gleevec) and sunitinib (Sutent). Epidemiology
GISTs occur in 10-20 per one million people. The true incidence might be higher, as novel laboratory methods are much more sensitive in diagnosing GISTs. The estimated incidence of GIST in the United States is approximately 5000 cases annually. : 1063  This makes GIST the most common form of sarcoma, which constitutes more than 70 types of cancer. The majority of GISTs present at ages 50–70 years. Across most of the age spectrum, the incidence of GIST is similar in men and women. : 1122 Adult GISTs are rare before age 40. Pediatric GISTs are considered to be biologically distinct.
Midol is a brand of over-the-counter analgesic drugs marketed for menstrual cramping and other effects related to premenstrual syndrome and menstruation. Various subbrands are formulated using different active ingredients. Midol is distributed by Bayer. Midol was originally sold in 1911 as a headache and toothache remedy that was considered safer because it did not use the narcotics typically used at the time. It was then promoted as a cure for hiccups claiming it controlled spasms, and finally as a remedy for menstrual cramps and bloating. A formulation sold in the 1980s was made with the sympathomimetic cinnamedrine. It had been reported to have abuse potential as an appetite suppressant and sympathomimetic agent. The "Midol Complete" formulation consists of:

Acetaminophen 500 mg (pain reliever)
Caffeine 60 mg  (stimulant)
Pyrilamine maleate 15 mg (antihistamine)The "Extended Relief" formulation consists of:

Naproxen sodium 220 mg (NSAID, pain reliever/fever reducer)The "Teen" formulation consists of:

Acetaminophen 500 mg (pain reliever)
Pamabrom 25 mg (diuretic)The "Liquid Gels" formulation consists of:

Ibuprofen 200 mg (NSAID, pain reliever)The "PM" formulation consists of:

Acetaminophen 500 mg (pain reliever)
Diphenhydramine citrate 38 mg (sedative antihistamine)There are concerns drugs like Midol, which is an NSAID, increases risk of bleeding, kidney damage and has other negative effects on cardiovascular system. References
External links
Official website